bioAffinity Technologies (BIAFW) Stock
Company Profile
Price: $2.00
Market Cap: $26.98M
Exchange: NASDAQ
CEO: Ms. Maria Zannes J.D.
Sector: Healthcare
Industry: Medical - Diagnostics & Research
Employees: -0.00B
Headquarters: None, None
Website: bioAffinity Technologies
Business Summary
bioAffinity Technologies, Inc. operates as a development-stage company addressing the significant unmet need for non-invasive, early-stage cancer diagnosis and treatment. The firm develops proprietary in-vitro diagnostic tests and targeted cancer therapeutics using breakthrough technology that preferentially targets cancer cells. The company was founded on March 26, 2014 and is headquartered in San Antonio, TX.
bioAffinity Technologies Chart
bioAffinity Technologies Earnings
This section highlight's bioAffinity Technologies's earnings, including earnings call transcripts, earnings surprises, and key dates.
bioAffinity Technologies Earnings Call Transcripts
| Transcript | Quarter | Year | Date | Estimated EPS | Actual EPS |
|---|
bioAffinity Technologies Earnings Dates
When is the next earnings date for BIAFW?
Date:Status: Unconfirmed
Time of Day:
Estimated EPS: $-
When was the last earnings date for BIAFW?
Date: 2023-09-29Fiscal Date Ending: 2023-09-30
EPS: $-0.00
Estimated EPS: $-
Revenue: $298.48K
Estimated Revenue: $-
Financial Statements
This section provides financial statements for bioAffinity Technologiesincluding income statements, balance sheets, and cash flow statements, both annually and quarterly.
Annual Income Statement
| Breakdown | 2019-12-31 | 2020-12-31 | 2021-12-31 | 2022-12-31 | 2023-12-31 |
|---|---|---|---|---|---|
| Revenue | $- | $- | $- | $4.80K | $2.53M |
| Cost of Revenue | $40.28K | $22.24K | $4.82K | $-0.00B | $1.99M |
| Gross Profit | $-40.28K | $-22.24K | $-4.82K | $4.34K | $542.02K |
| Gross Profit Ratio | 0.00% | 0.00% | 0.00% | 90.28% | 21.40% |
| Research and Development Expenses | $1.85M | $1.61M | $1.33M | $1.29M | $1.72M |
| General and Administrative Expenses | $- | $994.34K | $880.77K | $2.73M | $6.79M |
| Selling and Marketing Expenses | $- | $- | $- | $- | $- |
| Selling General and Administrative Expenses | $1.20M | $994.34K | $880.77K | $2.73M | $6.79M |
| Other Expenses | $- | $-4.28M | $724.93K | $-1.87M | $-27.80K |
| Operating Expenses | $3.05M | $2.60M | $2.21M | $4.02M | $8.52M |
| Cost and Expenses | $3.09M | $2.60M | $2.21M | $4.02M | $10.51M |
| Interest Income | $2.78K | $1.07K | $-0.00B | $46.71K | $122.13K |
| Interest Expense | $214.83K | $382.17K | $1.00M | $2.53M | $37.12K |
| Depreciation and Amortization | $40.28K | $22.24K | $4.82K | $10.18K | $249.59K |
| EBITDA | $-3.05M | $-6.86M | $-1.48M | $-5.82M | $-7.72M |
| EBITDA Ratio | 0.00% | 0.00% | 0.00% | -121196.96% | -304.98% |
| Operating Income | $-3.09M | $-2.60M | $-2.21M | $-4.01M | $-7.97M |
| Operating Income Ratio | 0.00% | 0.00% | 0.00% | -83511.51% | -314.84% |
| Total Other Income Expenses Net | $-212.06K | $-4.66M | $-4.12M | $-4.14M | $57.21K |
| Income Before Tax | $-3.30M | $-7.27M | $-6.32M | $-8.15M | $-7.92M |
| Income Before Tax Ratio | 0.00% | 0.00% | 0.00% | -169720.05% | -312.58% |
| Income Tax Expense | $3.20K | $2.75K | $1.95K | $2.46K | $20.99K |
| Net Income | $-3.31M | $-7.27M | $-6.33M | $-8.15M | $-7.94M |
| Net Income Ratio | 0.00% | 0.00% | 0.00% | -169771.25% | -313.41% |
| EPS | $-0.45 | $-0.99 | $-0.86 | $-1.81 | $-0.91 |
| EPS Diluted | $-0.45 | $-0.99 | $-0.86 | $-1.81 | $-0.91 |
| Weighted Average Shares Outstanding | 7.38M | 7.38M | 7.38M | 4.50M | 8.75M |
| Weighted Average Shares Outstanding Diluted | 7.38M | 7.38M | 7.38M | 4.50M | 8.75M |
| SEC Filing | Source | Source | Source | Source | Source |
Quarterly Income Statement
| Breakdown | 2020-12-31 | 2021-03-31 | 2021-06-30 | 2021-09-30 | 2021-12-31 | 2022-03-31 | 2022-06-30 | 2022-09-30 | 2022-12-31 | 2023-03-31 | 2023-06-30 | 2023-09-30 | 2023-12-31 | 2024-03-31 | 2024-06-30 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $- | $- | $- | $- | $- | $- | $1.31K | $1.15K | $2.35K | $-0.00B | $19.74K | $298.48K | $2.21M | $2.41M | $2.40M |
| Cost of Revenue | $- | $1.64K | $1.19K | $1.19K | $-0.00B | $1.04K | $-0.00B | $-0.00B | $-0.00B | $-0.00B | $1.23K | $74.70K | $1.81M | $1.72M | $1.56M |
| Gross Profit | $- | $-1.64K | $-1.19K | $-1.19K | $--0.00B | $-1.04K | $1.16K | $1.00K | $2.17K | $-0.00B | $18.50K | $223.78K | $399.71K | $683.31K | $838.87K |
| Gross Profit Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 88.82% | 87.30% | 92.54% | 90.55% | 93.75% | 74.97% | 18.06% | 28.40% | 34.99% |
| Research and Development Expenses | $410.54K | $304.22K | $286.95K | $364.74K | $370.13K | $374.52K | $335.87K | $380.69K | $197.25K | $389.25K | $370.38K | $330.38K | $528.17K | $442.60K | $453.89K |
| General and Administrative Expenses | $391.18K | $186.99K | $242.62K | $161.55K | $289.62K | $352.52K | $349.41K | $596.48K | $1.30M | $- | $1.43M | $2.02M | $2.21M | $- | $- |
| Selling and Marketing Expenses | $- | $- | $- | $- | $- | $- | $- | $- | $130.25K | $- | $- | $- | $- | $- | $- |
| Selling General and Administrative Expenses | $391.18K | $186.99K | $242.62K | $161.55K | $289.62K | $352.52K | $349.41K | $596.48K | $1.43M | $1.17M | $1.43M | $2.02M | $2.21M | $2.19M | $2.47M |
| Other Expenses | $- | $-111.48K | $1.89M | $-852.16K | $-199.17K | $404.19K | $782.80K | $-3.05M | $85.06K | $19.54M | $34.03M | $89.29K | $-15.30K | $4.51K | $-0.00B |
| Operating Expenses | $2.03M | $491.21K | $529.57K | $526.29K | $659.75K | $727.04K | $685.28K | $977.16K | $1.63M | $1.56M | $1.80M | $2.44M | $2.74M | $2.63M | $2.93M |
| Cost and Expenses | $2.03M | $491.21K | $529.57K | $526.29K | $659.75K | $727.04K | $685.43K | $977.31K | $1.63M | $1.56M | $1.80M | $2.52M | $4.56M | $4.35M | $4.49M |
| Interest Income | $106.43K | $-0.00B | $- | $-0.00B | $-0.00B | $-0.00B | $-0.00B | $-0.00B | $45.86K | $37.00K | $44.12K | $27.19K | $12.16K | $6.13K | $5.19K |
| Interest Expense | $- | $111.55K | $116.92K | $135.36K | $638.03K | $1.15M | $399.26K | $889.09K | $96.70K | $37.00M | $1.36K | $-8.79K | $25.32K | $23.55K | $22.25K |
| Depreciation and Amortization | $2.34K | $1.64K | $1.19K | $1.19K | $-0.00B | $1.04K | $1.04K | $-0.00B | $7.33K | $21.68K | $21.55K | $57.57K | $148.79K | $149.64K | $151.07K |
| EBITDA | $-799.38K | $-601.04K | $1.60M | $-1.38M | $-857.73K | $-321.24K | $312.25K | $-4.03M | $-1.57M | $-1.54M | $-1.71M | $-2.24M | $-2.19M | $-1.80M | $-1.94M |
| EBITDA Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 23909.11% | -350373.39% | -66946.04% | -166806.19% | -8677.04% | -751.93% | -99.11% | -74.62% | -80.78% |
| Operating Income | $-801.72K | $-491.21K | $-529.57K | $-526.29K | $-659.75K | $-727.04K | $311.21K | $-976.16K | $-1.62M | $-1.56M | $-1.78M | $-2.29M | $-2.34M | $-1.95M | $-2.09M |
| Operating Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 23829.48% | -84883.13% | -69213.21% | -169160.69% | -9009.78% | -768.72% | -105.83% | -80.84% | -87.08% |
| Total Other Income Expenses Net | $-1.33M | $-111.48K | $2.13M | $-852.16K | $-4.28M | $-742.82K | $-399.26K | $-3.94M | $-50.84K | $37.00K | $42.76M | $5.91K | $-28.46K | $-12.91K | $-17.06K |
| Income Before Tax | $-2.14M | $-714.23K | $1.48M | $-1.51M | $-5.58M | $-1.47M | $-88.05K | $-4.92M | $-1.67M | $-1.52M | $-1.74M | $-2.29M | $-2.37M | $-1.96M | $-2.10M |
| Income Before Tax Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | -6742.11% | -427752.87% | -71380.35% | -165143.43% | -8793.12% | -766.74% | -107.12% | -81.37% | -87.79% |
| Income Tax Expense | $- | $1.95K | $2.24M | $-716.80K | $438.86K | $2.16K | $399.26K | $-0.00B | $2.16K | $11.82K | $4.59K | $-2.29K | $2.29K | $3.67K | $5.42K |
| Net Income | $-2.14M | $-716.18K | $1.48M | $-1.51M | $-5.58M | $-1.47M | $-487.32K | $-4.92M | $-1.68M | $-1.53M | $-1.74M | $-2.29M | $-2.37M | $-1.96M | $-2.11M |
| Net Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | -37313.71% | -427778.96% | -71472.38% | -166426.71% | -8816.36% | -767.51% | -107.22% | -81.53% | -88.01% |
| EPS | $-0.80 | $-0.27 | $0.54 | $-0.57 | $-2.08 | $-0.55 | $-0.18 | $-1.17 | $-0.20 | $-0.18 | $-0.20 | $-0.26 | $-0.26 | $-0.20 | $-0.19 |
| EPS Diluted | $-0.80 | $-0.26 | $0.54 | $-0.55 | $-2.04 | $-0.54 | $-0.18 | $-1.17 | $-0.20 | $-0.18 | $-0.20 | $-0.26 | $-0.26 | $-0.20 | $-0.19 |
| Weighted Average Shares Outstanding | 2.67M | 2.67M | 2.73M | 2.68M | 2.68M | 2.68M | 2.69M | 4.20M | 8.38M | 8.43M | 8.52M | 8.70M | 9.25M | 9.92M | 11.39M |
| Weighted Average Shares Outstanding Diluted | 2.67M | 2.73M | 2.73M | 2.73M | 2.73M | 2.73M | 2.73M | 4.20M | 8.38M | 8.43M | 8.52M | 8.70M | 9.25M | 9.92M | 11.39M |
| SEC Filing | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source |
Annual Balance Sheet
| Breakdown | 2019-12-31 | 2020-12-31 | 2021-12-31 | 2022-12-31 | 2023-12-31 |
|---|---|---|---|---|---|
| Cash and Cash Equivalents | $578.48K | $83.11K | $1.36M | $11.41M | $2.82M |
| Short Term Investments | $- | $- | $- | $- | $- |
| Cash and Short Term Investments | $578.48K | $83.11K | $1.36M | $11.41M | $2.82M |
| Net Receivables | $1.53K | $1.53K | $1.53K | $10.49K | $811.67K |
| Inventory | $- | $28.35K | $71.85K | $5.54K | $18.48K |
| Other Current Assets | $37.49K | $5.67K | $4.22K | $119.77K | $321.02K |
| Total Current Assets | $617.51K | $118.66K | $1.44M | $11.96M | $3.97M |
| Property Plant Equipment Net | $28.80K | $9.45K | $4.63K | $214.44K | $1.99M |
| Goodwill | $- | $- | $- | $- | $1.40M |
| Intangible Assets | $- | $- | $- | $- | $833.47K |
| Goodwill and Intangible Assets | $- | $- | $- | $- | $2.24M |
| Long Term Investments | $- | $- | $- | $- | $- |
| Tax Assets | $- | $- | $- | $- | $- |
| Other Non-Current Assets | $12.50K | $17.50K | $10.44K | $6.00K | $16.06K |
| Total Non-Current Assets | $41.30K | $26.95K | $15.07K | $220.44K | $4.25M |
| Other Assets | $- | $- | $- | $- | $- |
| Total Assets | $658.81K | $145.60K | $1.45M | $12.18M | $8.22M |
| Account Payables | $103.42K | $191.39K | $230.41K | $345.04K | $604.79K |
| Short Term Debt | $4.01M | $9.95M | $11.20M | $251.75K | $460.17K |
| Tax Payables | $- | $- | $- | $- | $- |
| Deferred Revenue | $- | $- | $- | $- | $33.06K |
| Other Current Liabilities | $579.93K | $976.10K | $1.60M | $541.89K | $1.15M |
| Total Current Liabilities | $4.69M | $11.12M | $13.04M | $1.14M | $2.25M |
| Long Term Debt | $- | $53.47K | $160.18K | $- | $1.12M |
| Deferred Revenue Non-Current | $- | $- | $- | $- | $- |
| Deferred Tax Liabilities Non-Current | $- | $- | $- | $- | $- |
| Other Non-Current Liabilities | $- | $4.04M | $4.04M | $596.79K | $- |
| Total Non-Current Liabilities | $- | $4.10M | $4.20M | $596.79K | $1.12M |
| Other Liabilities | $- | $- | $--0.00B | $-596.79K | $- |
| Total Liabilities | $4.69M | $15.22M | $17.24M | $1.14M | $3.37M |
| Preferred Stock | $4.04M | $4.04M | $4.04M | $12.18B | $- |
| Common Stock | $18.72K | $18.72K | $18.74K | $58.67K | $65.76K |
| Retained Earnings | $-14.92M | $-22.19M | $-28.51M | $-36.67M | $-44.60M |
| Accumulated Other Comprehensive Income Loss | $-18.72K | $-4.04M | $-4.04M | $- | $- |
| Other Total Stockholders Equity | $6.84M | $7.10M | $12.70M | $-12.13B | $49.39M |
| Total Stockholders Equity | $-4.04M | $-15.07M | $-15.79M | $11.04M | $4.86M |
| Total Equity | $-4.04M | $-15.07M | $-15.79M | $11.04M | $4.86M |
| Total Liabilities and Stockholders Equity | $658.81K | $145.60K | $1.45M | $12.18M | $8.22M |
| Minority Interest | $- | $- | $- | $- | $- |
| Total Liabilities and Total Equity | $658.81K | $145.60K | $1.45M | $12.18M | $8.22M |
| Total Investments | $- | $- | $- | $- | $- |
| Total Debt | $4.01M | $10.01M | $11.36M | $251.75K | $1.58M |
| Net Debt | $3.43M | $9.92M | $10.00M | $-11.16M | $-1.24M |
Quarterly Balance Sheet
| Breakdown | 2020-12-31 | 2021-03-31 | 2021-09-30 | 2021-12-31 | 2022-03-31 | 2022-06-30 | 2022-09-30 | 2022-12-31 | 2023-03-31 | 2023-06-30 | 2023-09-30 | 2023-12-31 | 2024-03-31 | 2024-06-30 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash and Cash Equivalents | $83.11K | $-83.11K | $243.83K | $1.36M | $1.03M | $214.40K | $13.50M | $11.41M | $9.77M | $8.28M | $4.51M | $2.82M | $2.45M | $801.31K |
| Short Term Investments | $- | $166.22K | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Cash and Short Term Investments | $83.11K | $83.11K | $243.83K | $1.36M | $1.03M | $214.40K | $13.50M | $11.41M | $9.77M | $8.28M | $4.51M | $2.82M | $2.45M | $801.31K |
| Net Receivables | $- | $- | $- | $1.53K | $6.86K | $7.82K | $9.93K | $10.49K | $11.03K | $90.23K | $1.11M | $811.67K | $1.12M | $1.60M |
| Inventory | $- | $- | $- | $71.85K | $5.80K | $5.66K | $5.71K | $5.54K | $11.34K | $10.10K | $9.91K | $18.48K | $9.49K | $29.77K |
| Other Current Assets | $35.55K | $- | $102.31K | $4.22K | $17.42K | $15.53K | $8.83K | $119.77K | $134.31K | $128.19K | $142.11K | $321.02K | $344.90K | $253.73K |
| Total Current Assets | $118.66K | $83.11K | $346.13K | $1.44M | $1.11M | $327.25K | $14.05M | $11.96M | $10.23M | $8.66M | $6.01M | $3.97M | $3.93M | $2.68M |
| Property Plant Equipment Net | $9.45K | $- | $5.43K | $4.63K | $3.59K | $2.55K | $1.78K | $214.44K | $225.07K | $207.38K | $2.17M | $1.99M | $1.88M | $1.75M |
| Goodwill | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $1.15M | $1.40M | $1.40M | $1.40M |
| Intangible Assets | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $848.06K | $833.47K | $818.89K | $804.31K |
| Goodwill and Intangible Assets | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $2.00M | $2.24M | $2.22M | $2.21M |
| Long Term Investments | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Tax Assets | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Other Non-Current Assets | $17.50K | $-83.11K | $2.50K | $10.44K | $243.80K | $610.95K | $6.00K | $6.00K | $6.92K | $6.92K | $16.06K | $16.06K | $16.06K | $19.68K |
| Total Non-Current Assets | $26.95K | $-83.11K | $7.93K | $15.07K | $247.40K | $613.50K | $7.78K | $220.44K | $231.99K | $214.30K | $4.18M | $4.25M | $4.12M | $3.98M |
| Other Assets | $- | $- | $- | $- | $- | $- | $- | $- | $- | $--0.00B | $--0.00B | $- | $--0.00B | $- |
| Total Assets | $145.60K | $- | $354.06K | $1.45M | $1.35M | $940.75K | $14.06M | $12.18M | $10.46M | $8.87M | $10.19M | $8.22M | $8.05M | $6.66M |
| Account Payables | $191.39K | $- | $259.49K | $230.41K | $247.69K | $585.15K | $149.87K | $345.04K | $146.54K | $174.40K | $827.41K | $604.79K | $383.99K | $848.10K |
| Short Term Debt | $9.95M | $- | $10.33M | $11.20M | $11.78M | $11.12M | $815.12K | $251.75K | $168.43K | $42.33K | $449.14K | $460.17K | $474.10K | $482.96K |
| Tax Payables | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Deferred Revenue | $- | $- | $- | $- | $- | $- | $- | $- | $- | $42.75K | $38.25K | $33.06K | $30.17K | $26.14K |
| Other Current Liabilities | $976.10K | $- | $1.34M | $1.60M | $1.86M | $1.97M | $499.20K | $541.89K | $481.34K | $515.66K | $643.79K | $1.15M | $883.32K | $969.09K |
| Total Current Liabilities | $11.12M | $- | $11.93M | $13.04M | $13.88M | $13.68M | $1.46M | $1.14M | $796.30K | $775.15K | $1.96M | $2.25M | $1.77M | $2.33M |
| Long Term Debt | $53.47K | $- | $71.11K | $160.18K | $149.69K | $- | $- | $- | $- | $- | $1.24M | $1.12M | $23.04K | $22.77K |
| Deferred Revenue Non-Current | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Deferred Tax Liabilities Non-Current | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Other Non-Current Liabilities | $- | $- | $- | $4.04M | $4.04M | $4.04M | $474.87K | $596.79K | $146.54M | $- | $- | $- | $997.59K | $874.28K |
| Total Non-Current Liabilities | $53.47K | $- | $71.11K | $4.20M | $4.19M | $4.04M | $474.87K | $596.79K | $146.54M | $- | $1.24M | $1.12M | $1.02M | $897.05K |
| Other Liabilities | $- | $- | $- | $- | $- | $- | $-474.87K | $-596.79K | $-146.54M | $- | $- | $- | $- | $- |
| Total Liabilities | $11.17M | $- | $12.00M | $17.24M | $18.08M | $17.73M | $1.46M | $1.14M | $796.30K | $775.15K | $3.20M | $3.37M | $2.79M | $3.22M |
| Preferred Stock | $4.04M | $4.04M | $4.04M | $4.04M | $4.04M | $4.04M | $14.06B | $- | $-0.00B | $-0.00B | $-0.00B | $- | $- | $- |
| Common Stock | $18.72K | $- | $18.73K | $18.74K | $18.85K | $18.86K | $58.59K | $58.67K | $59.24K | $59.89K | $64.53K | $65.76K | $78.52K | $79.41K |
| Retained Earnings | $-22.19M | $- | $-22.94M | $-28.51M | $-29.99M | $-30.07M | $-34.99M | $-36.67M | $-38.20M | $-39.94M | $-42.23M | $-44.60M | $-46.57M | $-48.68M |
| Accumulated Other Comprehensive Income Loss | $--0.00B | $-15.07M | $- | $-0.00B | $-0.00B | $-4.04M | $- | $- | $--0.00B | $--0.00B | $-0.00B | $- | $- | $- |
| Other Total Stockholders Equity | $7.10M | $-0.00B | $7.23M | $8.66M | $9.20M | $13.27M | $-14.02B | $47.65M | $47.81M | $47.98M | $49.16M | $49.39M | $51.74M | $52.03M |
| Total Stockholders Equity | $-11.03M | $-11.03M | $-11.65M | $-15.79M | $-16.72M | $-16.79M | $12.60M | $11.04M | $9.67M | $8.10M | $6.99M | $4.86M | $5.26M | $3.43M |
| Total Equity | $-11.03M | $-11.03M | $-11.65M | $-15.79M | $-16.72M | $-16.79M | $12.60M | $11.04M | $9.67M | $8.10M | $6.99M | $4.86M | $5.26M | $3.43M |
| Total Liabilities and Stockholders Equity | $145.60K | $-11.03M | $354.06K | $1.45M | $1.35M | $940.75K | $14.06M | $12.18M | $10.46M | $8.87M | $10.19M | $8.22M | $8.05M | $6.66M |
| Minority Interest | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Total Liabilities and Total Equity | $145.60K | $-11.03M | $354.06K | $1.45M | $1.35M | $940.75K | $14.06M | $12.18M | $10.46M | $8.87M | $10.19M | $8.22M | $8.05M | $6.66M |
| Total Investments | $- | $166.22K | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Total Debt | $10.01M | $- | $10.40M | $11.36M | $11.93M | $11.12M | $815.12K | $251.75K | $168.43K | $42.33K | $1.69M | $1.58M | $1.49M | $1.38M |
| Net Debt | $9.92M | $83.11K | $10.16M | $10.00M | $10.90M | $10.91M | $-12.68M | $-11.16M | $-9.60M | $-8.24M | $-2.82M | $-1.24M | $-958.44K | $578.69K |
Annual Cash Flow Statement
| Breakdown | 2019-12-31 | 2020-12-31 | 2021-12-31 | 2022-12-31 | 2023-12-31 |
|---|---|---|---|---|---|
| Net Income | $-3.31M | $-7.27M | $-6.33M | $-8.15M | $-7.94M |
| Depreciation and Amortization | $40.28K | $22.24K | $4.82K | $10.18K | $249.59K |
| Deferred Income Tax | $- | $- | $3.84M | $- | $-964.09K |
| Stock Based Compensation | $- | $275.73K | $43.01K | $248.59K | $748.82K |
| Change in Working Capital | $322.01K | $482.62K | $632.82K | $114.20K | $900.79K |
| Accounts Receivables | $-0.00B | $- | $- | $-8.96K | $311.37K |
| Inventory | $- | $- | $- | $-5.54K | $-12.94K |
| Accounts Payables | $-39.82K | $87.97K | $39.02K | $114.64K | $-14.50K |
| Other Working Capital | $361.54K | $394.65K | $593.80K | $14.07K | $616.87K |
| Other Non Cash Items | $575.11K | $4.28M | $-244.35K | $3.71M | $964.09K |
| Net Cash Provided by Operating Activities | $-2.49M | $-2.21M | $-2.05M | $-4.07M | $-6.04M |
| Investments in Property Plant and Equipment | $-11.40K | $-2.89K | $- | $-219.99K | $-22.90K |
| Acquisitions Net | $- | $- | $- | $- | $-2.19M |
| Purchases of Investments | $- | $- | $- | $- | $- |
| Sales Maturities of Investments | $- | $- | $- | $- | $- |
| Other Investing Activities | $- | $- | $- | $- | $-2.21M |
| Net Cash Used for Investing Activities | $-11.40K | $-2.89K | $- | $-219.99K | $-2.21M |
| Debt Repayment | $-2.33M | $-1.72M | $-3.51M | $-694.98K | $-344.98K |
| Common Stock Issued | $- | $- | $- | $6.03M | $- |
| Common Stock Repurchased | $- | $- | $- | $--0.00B | $- |
| Dividends Paid | $- | $- | $- | $- | $- |
| Other Financing Activities | $- | $3.43M | $6.83M | $9.01M | $-344.98K |
| Net Cash Used Provided by Financing Activities | $2.33M | $1.72M | $3.33M | $14.34M | $-344.98K |
| Effect of Forex Changes on Cash | $- | $- | $- | $- | $-0.00B |
| Net Change in Cash | $-166.59K | $-495.38K | $1.28M | $10.05M | $-8.59M |
| Cash at End of Period | $578.48K | $83.11K | $1.36M | $11.41M | $2.82M |
| Cash at Beginning of Period | $745.08K | $578.48K | $83.11K | $1.36M | $11.41M |
| Operating Cash Flow | $-2.49M | $-2.21M | $-2.05M | $-4.07M | $-6.04M |
| Capital Expenditure | $-11.40K | $-2.89K | $- | $-219.99K | $-22.90K |
| Free Cash Flow | $-2.50M | $-2.21M | $-2.05M | $-4.29M | $-6.06M |
Quarterly Cash Flow Statement
| Breakdown | 2020-12-31 | 2021-03-31 | 2021-06-30 | 2021-09-30 | 2021-12-31 | 2022-03-31 | 2022-06-30 | 2022-09-30 | 2022-12-31 | 2023-03-31 | 2023-06-30 | 2023-09-30 | 2023-12-31 | 2024-03-31 | 2024-06-30 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net Income | $-2.14M | $-716.18K | $1.48M | $-1.51M | $-5.58M | $-1.47M | $-88.05K | $-4.92M | $-1.67M | $-1.53M | $-1.74M | $-2.29M | $-2.37M | $-1.96M | $-2.11M |
| Depreciation and Amortization | $2.34K | $1.64K | $1.19K | $1.19K | $-0.00B | $1.04K | $1.04K | $-0.00B | $7.33K | $21.68K | $21.55K | $57.57K | $148.79K | $149.64K | $151.07K |
| Deferred Income Tax | $- | $- | $-239.20K | $- | $4.08M | $- | $- | $- | $- | $-405.82K | $170.25M | $-4.84B | $-722.47K | $- | $- |
| Stock Based Compensation | $76.73K | $58.25K | $94.58K | $-20.31K | $-89.52K | $106.05K | $26.68K | $79.01K | $36.85K | $157.61K | $170.25K | $186.44K | $234.51K | $283.71K | $286.19K |
| Change in Working Capital | $251.40K | $152.26K | $188.06K | $39.42K | $253.09K | $156.94K | $452.20K | $-742.04K | $247.09K | $-175.55K | $188.42K | $514.36K | $373.56K | $-817.51K | $140.59K |
| Accounts Receivables | $-0.00B | $--0.00B | $- | $-0.00B | $- | $-5.33K | $--0.00B | $-2.11K | $-8.96K | $-538.00K | $-79.20K | $-64.72K | $239.53K | $-311.94K | $-472.02K |
| Inventory | $- | $- | $- | $- | $- | $-5.80K | $-0.00B | $--0.00B | $-0.00B | $-5.79K | $1.23K | $-0.00B | $-8.58K | $9.00K | $-20.28K |
| Accounts Payables | $- | $57.23K | $100.52K | $-89.66K | $-29.08K | $17.28K | $337.28K | $-435.29K | $195.36K | $-198.50K | $27.87K | $577.47K | $-421.34K | $-220.80K | $464.11K |
| Other Working Capital | $250.84K | $95.02K | $87.53K | $129.07K | $282.17K | $145.46K | $115.74K | $-304.58K | $60.52K | $566.75K | $238.52K | $1.41K | $563.95K | $-293.77K | $168.78K |
| Other Non Cash Items | $1.25M | $111.48K | $-1.89M | $852.16K | $679.75K | $574.02K | $-768.02K | $3.82M | $82.68K | $405.82K | $-170.25M | $4.84B | $722.47K | $1.11M | $616.52K |
| Net Cash Provided by Operating Activities | $-557.19K | $-392.55K | $-362.66K | $-641.33K | $-652.44K | $-633.97K | $-376.14K | $-1.76M | $-1.30M | $-1.53M | $-1.36M | $-1.53M | $-1.62M | $-2.35M | $-1.53M |
| Investments in Property Plant and Equipment | $--0.00B | $- | $- | $- | $- | $- | $- | $- | $-219.99K | $-32.31K | $-3.86K | $--0.00B | $13.44K | $-41.39K | $-28.29K |
| Acquisitions Net | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $-2.19M | $2.19M | $- | $- |
| Purchases of Investments | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Sales Maturities of Investments | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Other Investing Activities | $- | $- | $- | $- | $- | $- | $- | $- | $-220.00K | $-32.31M | $- | $- | $-2.21M | $- | $- |
| Net Cash Used for Investing Activities | $--0.00B | $- | $- | $- | $- | $- | $- | $- | $-219.99K | $-32.31K | $-3.86K | $-2.19M | $13.44K | $-41.39K | $-28.29K |
| Debt Repayment | $- | $-537.26K | $-650.00K | $- | $- | $-475.00K | $-34.97K | $-31.61K | $-563.37K | $-83.32K | $-126.10K | $-50.77K | $-84.81K | $-60.94K | $-91.29K |
| Common Stock Issued | $- | $- | $- | $- | $- | $-117.99K | $-402.52K | $14.34M | $6.03M | $- | $- | $6.03B | $-6.03B | $2.08M | $-0.00B |
| Common Stock Repurchased | $- | $- | $- | $- | $- | $- | $- | $- | $--0.00B | $- | $- | $- | $- | $- | $- |
| Dividends Paid | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Other Financing Activities | $462.96K | $537.26K | $650.00K | $370.00K | $1.77M | $301.36K | $-437.49K | $739.12K | $-6.03M | $-83.32K | $-126.10K | $-50.77K | $6.03B | $102.62M | $- |
| Net Cash Used Provided by Financing Activities | $462.96K | $537.26K | $650.00K | $370.00K | $1.77M | $301.36K | $-437.49K | $15.04M | $-563.56K | $-83.32K | $-126.10K | $-50.77K | $-84.81K | $2.02M | $-91.14K |
| Effect of Forex Changes on Cash | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $171.74M | $1.19B | $-1.36B | $- | $- |
| Net Change in Cash | $-94.23K | $144.71K | $287.34K | $-271.33K | $1.12M | $-332.60K | $-813.63K | $13.28M | $-2.08M | $-1.64M | $-1.49M | $-3.77M | $-1.69M | $-368.40K | $-1.65M |
| Cash at End of Period | $83.11K | $227.82K | $515.16K | $243.83K | $1.36M | $1.03M | $214.40K | $13.50M | $11.41M | $9.77M | $8.28M | $4.51M | $2.82M | $2.45M | $801.31K |
| Cash at Beginning of Period | $177.34K | $83.11K | $227.82K | $515.16K | $243.83K | $1.36M | $1.03M | $214.40K | $13.50M | $11.41M | $9.77M | $8.28M | $4.51M | $2.82M | $2.45M |
| Operating Cash Flow | $-557.19K | $-392.55K | $-362.66K | $-641.33K | $-652.44K | $-633.97K | $-376.14K | $-1.76M | $-1.30M | $-1.53M | $-1.36M | $-1.53M | $-1.62M | $-2.35M | $-1.53M |
| Capital Expenditure | $--0.00B | $- | $- | $- | $- | $- | $- | $- | $-219.99K | $-32.31K | $-3.86K | $--0.00B | $13.44K | $-41.39K | $-28.29K |
| Free Cash Flow | $-557.19K | $-392.55K | $-362.66K | $-641.33K | $-652.44K | $-633.97K | $-376.14K | $-1.76M | $-1.52M | $-1.56M | $-1.36M | $-1.53M | $-1.60M | $-2.39M | $-1.56M |
bioAffinity Technologies Dividends
Understand bioAffinity Technologies's dividend history, dividend yield, payout ratio, and more.
Dividend Yield
-
Dividend Payout Ratio
-
Dividend Paid & Capex Coverage Ratio
263.64x
bioAffinity Technologies Dividend History
| Dividend | Adjusted Dividend | Date | Record Date | Payment Date | Declaration Date |
|---|
Valuation
Analyze the market cap, enterprise value, and valuation metrics for bioAffinity Technologies.
Market Cap & Enterprise Value
Market Cap: $26.98M
Enterprise Value: $11.62M
Valuation Ratios
P/E Ratio: -1.62
P/B Ratio: 2.65
P/CF Ratio: -2.13
Valuation Multiples
E/V to Sales: 4.59
E/V to EBITDA: -1.50
Market Cap & Enterprise Value
Market capitalization and enterprise value provide an understanding of a company's market value and total value, respectively.
- Market Cap: The total market value of a company's outstanding shares of stock. It represents the company's equity value and is calculated by multiplying the current share price by the total number of outstanding shares.
- Enterprise Value (EV): A measure of a company's total value, often seen as a more comprehensive alternative to equity market capitalization. It includes market cap plus debt, minority interest, and preferred shares, minus total cash and cash equivalents.
Valuation Ratios
Valuation ratios are used to evaluate the value of a company compared to its earnings, book value, and cash flow.
- P/E Ratio: Price to Earnings Ratio, indicating how much investors are willing to pay for a dollar of earnings.
- P/B Ratio: Price to Book Ratio, comparing the company's market value to its book value. A lower ratio may indicate undervaluation.
- P/CF Ratio: Price to Cash Flow Ratio, evaluating the market value relative to the operating cash flow. A lower ratio can signal a more attractive investment.
Valuation Multiples
Valuation multiples help assess a company's value relative to its revenue and earnings.
- EV to Sales: Enterprise Value to Sales, comparing the enterprise value to sales revenue. A lower ratio can indicate a more attractive investment.
- EV to EBITDA: Enterprise Value to EBITDA, comparing the enterprise value to earnings before interest, taxes, depreciation, and amortization. A lower ratio suggests a company may be undervalued.
bioAffinity Technologies Growth
View income_statement_chart2_annual_data financial growth metrics for bioAffinity Technologies, including income statement, balance sheet, and cash flow growth.
Income Growth
Revenue Growth: -0.36%
Operating Income Growth: -7.33%
Cash Flow Growth
Net Income Growth: -7.57%
Free Cash Flow Growth: 34.63%
Balance Sheet Growth
Total Assets Growth: -17.30%
Total Liabilities Growth: 15.44%
Income Growth
This section highlights key metrics related to income growth, showing how the company’s revenue and operating income have changed over time:
- Revenue Growth: The increase in a company's sales over time. It is a measure of how quickly the company is growing its revenue. This chart shows the historical trend of revenue growth.
- Operating Income Growth: The growth rate of a company's operating income, which is the income earned from its normal business operations. This chart helps to assess the company's operational efficiency and profitability growth over time.
Cash Flow Growth
This section highlights key metrics on the company's cash flow growth, reflecting changes in net income and free cash flow over time.
- Net Income Growth: The increase in a company's net profit over time. It reflects the company's ability to increase its profitability. This chart provides insight into how the company's bottom line has grown.
- Free Cash Flow Growth: The growth in a company's free cash flow, which is the cash generated by the company after accounting for capital expenditures. This chart is important for understanding the company's financial flexibility and ability to fund operations and growth.
Balance Sheet Growth
This section highlight key metrics related to balance sheet growth, which indicate how the company’s total assets and liabilities have changed over time:
- Total Assets Growth: The rate at which a company's total assets are increasing over time. This chart indicates how the company's asset base is expanding, which can be a sign of growth and investment in future operations.
- Total Liabilities Growth: The rate at which a company's total liabilities are increasing over time. This chart helps to assess the company's financial leverage and risk over time.
Peers: Medical - Diagnostics & Research
This section provides companies within the same sector, on the same exchange, and of similar market capitalization, allowing comparisons of key financial indicators among peers.
| Company | Market Cap | Price | EPS | P/E Ratio | P/B Ratio |
|---|---|---|---|---|---|
bioAffinity Technologies, Inc.
BIAF
|
$24.55M | $1.82 | $-0.91 | $-1.62 | $2.65 |
AAP, Inc.
AAPJ
|
$622.96K | $0.00 | $0.00 | $-3.93 | $-1.05 |
Discount Print USA, Inc.
DPUI
|
$87.05K | $0.00 | $-0.01 | $-0.09 | $-0.10 |
China Dongsheng International, Inc.
CDSG
|
$72.56K | $0.00 | $0.00 | $-13.55 | $-13.65 |
Peak Bio, Inc.
PKBO
|
$4.16M | $0.18 | $0.00 | $-4398.92 | $-0.31 |
More metrics for bioAffinity Technologies
Access more key metrics, financials, ratios, and more with the links below.